初回経動脈化学塞栓療法を受けた残存肝癌または再発肝癌患者の治療における経動脈化学塞栓療法と定位放射線療法または定位アブレーション放射線療法との比較

基本情報

NCT ID

NCT02762266

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

13

治験依頼者名

Stanford University

概要

This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer that remain after attempts to remove the cancer have been made (residual) or has come back (recurrent). TACE is a minimally invasive, image-guided treatment procedure that uses a catheter to deliver both chemotherapy medication and embolization materials into the blood vessels that lead to the tumors. SBRT or SABR may be able to send radiation directly to the tumor and cause less damage to normal liver tissue. It is not yet known whether TACE is more effective than SBRT or SABR in treating patients with persistent or recurrent liver cancer who have undergone initial TACE.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)